Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Current Deferred Revenue (2016 - 2022)

Historic Current Deferred Revenue for Usana Health Sciences (USNA) over the last 10 years, with Q1 2022 value amounting to $19.6 million.

  • Usana Health Sciences' Current Deferred Revenue rose 2308.8% to $19.6 million in Q1 2022 from the same period last year, while for Jan 2022 it was $19.6 million, marking a year-over-year increase of 2308.8%. This contributed to the annual value of $19.6 million for FY2022, which is 2308.8% up from last year.
  • Usana Health Sciences' Current Deferred Revenue amounted to $19.6 million in Q1 2022, which was up 2308.8% from $16.0 million recorded in Q1 2021.
  • Usana Health Sciences' 5-year Current Deferred Revenue high stood at $19.6 million for Q1 2022, and its period low was $2.6 million during Q4 2018.
  • Moreover, its 4-year median value for Current Deferred Revenue was $14.9 million (2019), whereas its average is $13.0 million.
  • In the last 5 years, Usana Health Sciences' Current Deferred Revenue crashed by 1361.41% in 2018 and then skyrocketed by 42350.72% in 2019.
  • Usana Health Sciences' Current Deferred Revenue (Quarter) stood at $2.6 million in 2018, then skyrocketed by 423.51% to $13.9 million in 2019, then increased by 15.16% to $16.0 million in 2021, then grew by 23.09% to $19.6 million in 2022.
  • Its last three reported values are $19.6 million in Q1 2022, $16.0 million for Q1 2021, and $13.9 million during Q4 2019.